mHSPC VL

Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay

Details
Rana McKay and Alicia Morgans discuss the CYCLONE 3 trial in progress in high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Recent data from the ARASENS trial shows a survival benefit for treatment intensification with ADT + docetaxel + a novel hormonal agent, triplet therapy, vs ADT + docetaxel in selected patients. Yet, there is a significant medical need to expand therapeutic optio...

The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz

Details
Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies outlines the following 5 key questions for the field of mHSPC: Do all patients with mHSPC benefit from ADT intensification? When should we use triplet (ADT + ARSI + docetax...

8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam

Details
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable level...

The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore

Details
Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...

APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu discusses the changing landscape of metastatic hormone-sensitive prostate cancer treatment with Alicia Morgans. Dr. Yu provides an overview of the many important questions and concerns clinicians must address in sequencing treatment for mCRPC patients in light of novel hormone therapy agents and the opportunity for triplet therapy. Biographies: Evan Yu, MD , Professor, Department of Medici...

(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan

Details
In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the (AF...

Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal

Details
In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the exp...

From ADT to Triplet Therapy: Rethinking Treatment Paradigms in Metastatic Hormone Sensitive Prostate Cancer - Matthew Smith & Kim Chi

Details
Alicia Morgans converses with Matthew Smith and Kim Chi about the application of triplet therapy in metastatic hormone sensitive prostate cancer (mHSPC). Dr. Smith outlines the ARASENS study that tests the impact of adding darolutamide, an AR pathway inhibitor, to the standard treatment of androgen deprivation therapy (ADT) and docetaxel. The data suggest a significant survival advantage with trip...

Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Alicia Morgans presents the treatment of vulnerable/frail patients with metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC...

Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke

Details
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Caroline Clarke presents on health economics in metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Caroline S. Clarke, PhD, MSci, BA (Hons), Senior Research Associate in Health Economics, University College London, London, UK Related Content: APCCC 2022: Optimal Treatment for mHSPC from a Health Econo...